연구동향 분석

A Novel Simultaneous Determination of Sarpogrelate and its Active Metabolite (M-1) in Human Plasma, Using Liquid Chromatography-Tandem Mass Spectrometry: Clinical Application

고재욱 양정수 이수연 김정렬 조은기 허우성 2015년

논문상세정보
인용/피인용
' A Novel Simultaneous Determination of Sarpogrelate and its Active Metabolite (M-1) in Human Plasma, Using Liquid Chromatography-Tandem Mass Spectrometry: Clinical Application' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 의학
  • clinical study
  • core-shell-typechromatography
  • metabolite
  • sarpogrelate
  • simultaneous determination
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
7,664 0

0.0%

' A Novel Simultaneous Determination of Sarpogrelate and its Active Metabolite (M-1) in Human Plasma, Using Liquid Chromatography-Tandem Mass Spectrometry: Clinical Application' 의 참고문헌

  • Validated LC-MS/MS method for the determination of sarpogrelate in human plasma: application to a pharmacokinetic and bioequivalence study in Chinese volunteers
    Zhang C J Pharm Biomed Anal 53 : 546 ~ 551 [2010]
  • Validated LC-MS/MS method for the determination of sarpogrelate in human plasma: application to a pharmacokinetic and bioequivalence study in Chinese volunteers
    Zhang C J Pharm Biomed Anal 53 546-551 [2010]
  • Therapeutic potentials of sarpogrelate in cardiovascular disease
    Saini HK Cardiovasc Drug Rev 22 : 27 ~ 54 [2004]
  • Therapeutic potentials of sarpogrelate in cardiovascular disease
    Saini HK Cardiovasc Drug Rev 22 27-54 [2004]
  • Synthesis and 5-HT2A, 5-HT1A and alpha1-binding affinities of 2-[2-Hydroxy-3-(pyridin-3-yl-methyl)amino]-, 2-[2-hydroxy-3-(2-pyridin-2-yl-ethyl)amino]- and 2-[2-hydroxy-3-(4-N-methyl-piperazin-1-yl)-amino]propoxybenzaldehyde-O-(substituted) benzyl oximes
    Orlandini E Arch Pharm (Weinheim) 340 : 135 ~ 139 [2007]
  • Synthesis and 5-HT2A, 5-HT1A and alpha1-binding affinities of 2-[2-Hydroxy-3-(pyridin-3-yl-methyl)amino]-, 2-[2-hydroxy-3-(2-pyridin-2-yl-ethyl)amino]- and 2-[2-hydroxy-3-(4-N-methyl-piperazin-1-yl)-amino]propoxybenzaldehyde-O-(substituted) benzyl oximes
    Orlandini E Arch Pharm (Weinheim) 340 135-139 [2007]
  • Rapid and sensitive LC−MS–MS method for the determination of sarpogrelate in human plasma
    Patankar S Chromatographia 69 : 671 ~ 676 [2009]
  • Rapid and sensitive LC−MS–MS method for the determination of sarpogrelate in human plasma
    Patankar S Chromatographia 69 671-676 [2009]
  • Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444
    Ogawa T Eur J Pharmacol 457 : 107 ~ 114 [2002]
  • Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444
    Ogawa T Eur J Pharmacol 457 107-114 [2002]
  • Liquid chromatography tandem mass spectrometry method for the quantification of sarpogrelate, a selective 5-HT2A receptor antagonist, in plasma: application to a pre-clinical pharmacokinetic study
    Nirogi R Biomed Chromatogr 24 : 1159 ~ 1167 [2010]
  • Liquid chromatography tandem mass spectrometry method for the quantification of sarpogrelate, a selective 5-HT2A receptor antagonist, in plasma: application to a pre-clinical pharmacokinetic study
    Nirogi R Biomed Chromatogr 24 1159-1167 [2010]
  • Inverse agonist activity of sarpogrelate, a selective 5-HT2A-receptor antagonist, at the constitutively active human 5-HT2A receptor
    Muntasir HA J Pharmacol Sci 102 : 189 ~ 195 [2006]
  • Inverse agonist activity of sarpogrelate, a selective 5-HT2A-receptor antagonist, at the constitutively active human 5-HT2A receptor
    Muntasir HA J Pharmacol Sci 102 189-195 [2006]
  • Guidance for industry: Bioanalytical method validation
  • Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study
    Uchiyama S Cerebrovasc Dis 24 : 264 ~ 270 [2007]
  • Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study
    Uchiyama S Cerebrovasc Dis 24 264-270 [2007]
  • Comparison of pharmacokinetics between sarpogrelate hydrochloride immediate-release formulation and controlled-release formulation
    Kim TE Int J Clin Pharmacol Ther 51 : 114 ~ 119 [2013]
  • Comparison of pharmacokinetics between sarpogrelate hydrochloride immediate-release formulation and controlled-release formulation
    Kim TE Int J Clin Pharmacol Ther 51 114-119 [2013]
  • Binding and functional affinity of sarpogrelate, its metabolite m-1 and ketanserin for human recombinant alpha-1-adrenoceptor subtypes
    Israilova M Pharmacology 65 : 69 ~ 73 [2002]
  • Binding and functional affinity of sarpogrelate, its metabolite m-1 and ketanserin for human recombinant alpha-1-adrenoceptor subtypes
    Israilova M Pharmacology 65 69-73 [2002]